Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vanda Pharmaceuticals Inc. (VNDA)  
$5.05 0.01 (0.2%) as of 4:30 Mon 5/13


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 61,398,000
Market Cap: 310.06(M)
Last Volume: 832,955 Avg Vol: 701,733
52 Week Range: $3.38 - $6.66
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  803
Guru Rank Value     : 1
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 121,098 121,098 148,134 388,157
Total Sell Value $513,345 $513,345 $684,141 $2,735,436
Total People Sold 5 5 6 8
Total Sell Transactions 10 10 14 33
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 549
  Page 13 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2012-02-16 4 S $4.69 $53,254 D/D (11,350) 428,650     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2012-02-16 4 OE $0.00 $0 D/D 31,250 440,000     -
   Feeney John Joseph SVP & Chief Medical Officer   •       –      –    2012-02-16 4 S $4.65 $22,152 D/D (4,760) 14,927     -
   Feeney John Joseph SVP & Chief Medical Officer   •       –      –    2012-02-16 4 OE $0.00 $0 D/D 12,187 19,687     -
   Kelly James Patrick SVP, CFO, Sec & Treasurer   •       –      –    2011-08-29 4 B $5.99 $29,952 D/D 5,000 5,000 2.74     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2011-08-23 4 B $5.35 $42,353 D/D 7,920 390,000 2.81     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2011-08-22 4 B $5.34 $11,112 D/D 2,080 382,080 2.81     -
   Feeney John Joseph SVP & Chief Medical Officer   •       –      –    2011-02-18 5 S $7.25 $21,641 D/D (2,985) 4,515     -
   Feeney John Joseph SVP & Chief Medical Officer   •       –      –    2011-02-18 5 OE $0.00 $0 D/D 7,500 7,500     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2011-02-18 5 OE $0.00 $0 D/D 18,750 408,750     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2010-12-10 4 S $8.10 $669,176 D/D (82,600) 380,000     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2010-12-09 4 S $8.11 $141,100 D/D (17,400) 462,600     -
   Halak Brian K Director   –       •      –    2010-03-26 4 A $0.00 $0 D/D 7,276 7,276     -
   Karabelas Argeris N Director   –       •      –    2010-03-12 4 S $11.80 $2,360,000 I/I (200,000) 0     -
   Ramsay David Russ Former Director   –       –      –    2010-03-12 4 S $11.80 $2,360,000 I/I (200,000) 0     -
   Clark William D Sr. VP, Chief Business Officer   •       –      –    2010-02-19 4 S $10.65 $101,409 D/D (9,522) 168,279     -
   Feeney John Joseph Acting Chief Medical Officer   •       –      –    2010-02-19 4 S $10.56 $211,200 D/D (20,000) 0     -
   Feeney John Joseph Acting Chief Medical Officer   •       –      –    2010-02-18 4 OE $0.00 $0 D/D 20,000 20,000     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2010-02-18 4 OE $0.00 $0 D/D 75,000 480,000     -
   Clark William D Sr. VP, Chief Business Officer   •       –      –    2010-02-18 4 OE $0.00 $0 D/D 25,000 177,801     -
   Irish Stephanie Rast Acting CFO/Treasurer   •       –      –    2010-02-18 4 OE $0.00 $0 D/D 20,000 22,449     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-14 4 S $10.73 $589,181 I/I (54,900) 2,715,852     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-13 4 S $10.54 $912,065 I/I (86,500) 2,770,752     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-12 4 S $10.88 $298,310 I/I (27,419) 2,857,252     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-11 4 S $11.00 $392,641 I/I (35,681) 2,884,671     -
  549 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 13 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us